Latest news for Omni Health (OTC:OMHE) Stock

Omni Health Inc operates a pharmacy in Miami Beach, Florida. The company operates through its subsidiary as a vertically integrated company focused on healthcare and operating in the lucrative pharmaceutical, medical and wellness industries.

Omni Health Inc

PIXY

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) has outperformed the market over the past 15 years by 7.37% on an annualized basis producing an average annual return of 19.1%. Currently, Ameriprise Finl has a market capitalization of $49.45 billion. 
Buying $1000 In AMP: If an investor had bought $1000 of AMP stock 15 years ago, it would be worth $13,919.67 today based on a price of $502.50 for AMP at the time of writing.
<h3>Ameriprise Finl's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728682223_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Ameriprise Finl Stock In The Last 15 Years

Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) has outperformed the market over the past 5 years by 10.53% on an annualized basis producing an average annual return of 24.69%. Currently, Pure Storage has a market capitalization of $17.43 billion. 
Buying $100 In PSTG: If an investor had bought $100 of PSTG stock 5 years ago, it would be worth $305.05 today based on a price of $53.20 for PSTG at the time of writing.
<h3>Pure Storage's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728682218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PSTG

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

ZPTAW

Trading Halt: Halt status updated at 5:30:00 PM ET: Quotation Resumption: News and Resumption Times

ZPTA

Trading Halt: Halt status updated at 5:25:00 PM ET: Quotation Resumption: News and Resumption Times

JP Morgan Chase &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>) and Wells Fargo &amp; Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wfc#NYSE">WFC</a>) ended the week by reporting their quarterly results, kicking off the third quarter earnings season.&nbsp;Bank of America Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bac#NYSE">BAC</a>) is due to report its latest financial results on Tuesday, with The Goldman Sachs Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>), Citigroup Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/c#NYSE">C</a>) and Morgan Stanley(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ms#NYSE">MS</a>)&nbsp;due to also report next week.
<h3>JP Morgan Reported A&nbsp;Better-Than-Expected Interest Income&nbsp;</h3>
During the quarter ended in September, JP Morgan reported&nbsp;revenues rose 6% YoY to $43.3 billion, surpassing LSEG&rsquo;s consensus estimate of&nbsp;$41.63 billion. Results were fueled by investment banking fees that grew 31% as they brought in $2.27 billion.
On the other hand, JP Morgan reported that&nbsp;net income fell 2%&nbsp;to $12.9 billion, but earnings per share rose to $4.37, up from $4.33 as there were fewer outstanding shares in the latest quarter, surpassing FactSet&rsquo;s consensus estimate of $3.99 a share.
However,&nbsp;net interest income grew 3% to $23.5 billion, surpassing both StreetAccount&rsquo;s estimate of $22.73 billion and&nbsp;FactSet&rsquo;s estimate of $22.9 billion. Consequently, JP Morgan raised its full year guidance for net interest income up from $91 billion to about&nbsp;$92.5 billion.&nbsp;
JP Morgan has et aside more money to cover credit losses, more precisely $3.1 billion, compared ot last year&rsquo;s comparable quarter when it had only set aside $1.4 billion.
During the earnings call, CFO&nbsp;Jeremy Barnum&nbsp;described the consumer is doing fine&nbsp;and is on a solid footing.&nbsp;But CEO Jamie Dimon spoke of continuously monitoring geopolitical tensions that he described as &ldquo;treacherous and getting worse.&rdquo;&nbsp;In a statement where he referred to the unspeakable human suffering, with the outcome of conflicts possibly having far-reaching effects on both short-term economic outcomes and more importantly, the course of history.&nbsp;Dimon is one of the rare CEOs who goes beyond the scope of banking to view the bigger picture of the world, often giving solicited or unsolicited advice to global leaders.
All in all, the biggest American bank continues to thrive&nbsp;in a rising rate environment.
Wells Fargo continues to evolve and generate more income through fees.&nbsp;
Wells Fargo reported third-quarter revenue dropped to $20.37&nbsp;billion, reporting a profit of $1.42 per share as net income fell to&nbsp;$5.11 billion. Net interest income also fell 11% to&nbsp;$11.69 billion, but&nbsp;the decline was offset by higher fee income.
However, the bigger picture here is that the once the country&rsquo;s #1 home mortgage lender has evolved in recent years.
Earlier this year, the Biden administration lifted a consent order that was in place since 2016&nbsp;&nbsp;following a series of scandals that included fake customer accounts.&nbsp;Last month, Wells Fargo even agreed to work with U.S. bank regulators to improve its financial crimes risk management controls that detect suspicious activity and money laundering.&nbsp;The bottom line is that despite the YoY decline of both profit and revenue, they fell less than analysts had expected.&nbsp;
By reporting better than feared results, both Wells Fargo and JP Morgan have shown that the U.S. consumers proved to be more resilient than expected, suggesting that a soft landing is more likely than a recession.&nbsp;
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

General

JP Morgan And Wells Fargo Report Better Than Expected Q3 Results That Reflect Resilient U.S. Consumers

STOCK CLIMBS 1.5% AT HIGH POINT
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="818" height="795" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/11200904/Screen-Shot-2024-10-11-at-4.12.03-PM.png" alt="" class="wp-image-2234" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/11200904/Screen-Shot-2024-10-11-at-4.12.03-PM.png 818w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/11200904/Screen-Shot-2024-10-11-at-4.12.03-PM-300x292.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/11200904/Screen-Shot-2024-10-11-at-4.12.03-PM-768x746.png 768w" sizes="(max-width: 818px) 100vw, 818px" /></figure>
MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:37 AM on OCTOBER 11th, a significant trading signal occurred for MercadoLibre, Inc. as it demonstrated a Power Inflow at a price of $2074.55. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in MercadoLibre&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Mercado Libre&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open. Generally, it signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for MELI, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $2074.55. The returns on the High price ($2105.33) and Close price ($2091.28) after the Power Inflow are respectively 1.5% and 0.8%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.

Signals

MELI

Tradepulse Power Inflow Alert: Mercadolibre Inc. Rises Over 30 Points After Signal

Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Edgewell Personal Care, presenting an average target of $39.5, a high estimate of $41.00, and a low estimate of $37.00. A decline of 3.07% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1728680505_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Edgewell Personal Care by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edgewell Personal Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Edgewell Personal Care compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Edgewell Personal Care's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Edgewell Personal Care's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EPC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Edgewell Personal Care analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Edgewell Personal Care</h2>
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
<h3>Edgewell Personal Care's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Edgewell Personal Care's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -0.34%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Edgewell Personal Care's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Edgewell Personal Care's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Edgewell Personal Care's ROA stands out, surpassing industry averages. With an impressive ROA of 1.31%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.83.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Navigating 4 Analyst Ratings For Edgewell Personal Care

In the latest quarter, 6 analysts provided ratings for Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $106.33, along with a high estimate of $111.00 and a low estimate of $100.00. Witnessing a positive shift, the current average has risen by 4.58% from the previous average price target of $101.67.
<img src="https://www.benzinga.com/files/images/story/2024/1728680490_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Eastman Chemical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$111.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$107.00</td>
<td>$102.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eastman Chemical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Eastman Chemical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Eastman Chemical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eastman Chemical analyst ratings.</a>
<h2>All You Need to Know About Eastman Chemical</h2>
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
<h3>Key Indicators: Eastman Chemical's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Eastman Chemical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.68% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.73%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.12%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Eastman Chemical's ROA excels beyond industry benchmarks, reaching 1.55%. This signifies efficient management of assets and strong financial health.
Debt Management: Eastman Chemical's debt-to-equity ratio is below the industry average at 0.89, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Eastman Chemical Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

In the preceding three months, 18 analysts have released ratings for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for UnitedHealth Group, revealing an average target of $615.78, a high estimate of $680.00, and a low estimate of $591.00. Observing a 6.75% increase, the current average has risen from the previous average price target of $576.82. 
<img src="https://www.benzinga.com/files/images/story/2024/1728680474_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of UnitedHealth Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$675.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$680.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>David Toung</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$601.00</td>
<td>$546.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$604.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$630.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$640.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$615.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$647.00</td>
<td>$481.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$640.00</td>
<td>$597.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$615.00</td>
<td>$595.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UnitedHealth Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UnitedHealth Group compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for UnitedHealth Group's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into UnitedHealth Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/UNH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UnitedHealth Group analyst ratings.</a>
<h2>Discovering UnitedHealth Group: A Closer Look</h2>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>UnitedHealth Group's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: UnitedHealth Group's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 6.61%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: UnitedHealth Group's net margin excels beyond industry benchmarks, reaching 4.31%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): UnitedHealth Group's ROE excels beyond industry benchmarks, reaching 4.79%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.48%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 0.84, UnitedHealth Group faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring UnitedHealth Group Through Analyst Insights

Analysts' ratings for Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Encompass Health, revealing an average target of $106.0, a high estimate of $115.00, and a low estimate of $100.00. Surpassing the previous average price target of $100.57, the current average has increased by 5.4%.
<img src="https://www.benzinga.com/files/images/story/2024/1728680459_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Encompass Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$104.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Encompass Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Encompass Health compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Encompass Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Encompass Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Encompass Health analyst ratings.</a>
<h2>About Encompass Health</h2>
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
<h3>Encompass Health: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Encompass Health's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.61%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Encompass Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.71%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Encompass Health's ROE excels beyond industry benchmarks, reaching 6.33%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Encompass Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.8% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.6.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 8 Analyst Evaluations For Encompass Health

Ratings for eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $60.84, a high estimate of $70.00, and a low estimate of $46.00. Surpassing the previous average price target of $55.94, the current average has increased by 8.76%.
<img src="https://www.benzinga.com/files/images/story/2024/1728680450_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive eBay is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$58.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$46.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Lee Horowitz</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$53.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$59.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Nathan Feather</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to eBay. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of eBay compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for eBay's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into eBay's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EBAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on eBay analyst ratings.</a>
<h2>Discovering eBay: A Closer Look</h2>
EBay operates one of the largest e-commerce marketplaces in the world, with $73 billion in 2023 gross merchandise volume, or GMV, rendering the firm a top 10 global e-commerce company. The company generates revenue from listing fees, advertising, revenue-sharing arrangements with service providers, and managed payments, with its platform connecting more than 130 million buyers and roughly 20 million sellers across almost 190 global markets at the end of 2023. EBay generates just north of 50% of its GMV in international markets, with a large presence in the UK, Germany, and Australia.
<h3>Key Indicators: eBay's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: eBay displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 1.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.71%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): eBay's ROE excels beyond industry benchmarks, reaching 3.8%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.07%, the company showcases effective utilization of assets.
Debt Management: eBay's debt-to-equity ratio is below the industry average. With a ratio of 1.48, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EBAY

Key Takeaways From eBay Analyst Ratings

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 5.29% on an annualized basis producing an average annual return of 13.91%. Currently, Centene has a market capitalization of $38.08 billion. 
Buying $100 In CNC: If an investor had bought $100 of CNC stock 20 years ago, it would be worth $1,305.23 today based on a price of $72.39 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728680441_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Centene 20 Years Ago Would Be Worth Today

MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) has outperformed the market over the past 5 years by 2.61% on an annualized basis producing an average annual return of 16.77%. Currently, MongoDB has a market capitalization of $21.64 billion. 
Buying $1000 In MDB: If an investor had bought $1000 of MDB stock 5 years ago, it would be worth $2,129.19 today based on a price of $293.00 for MDB at the time of writing.
<h3>MongoDB's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728680436_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today

Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.0, a high estimate of $28.00, and a low estimate of $24.00. A 4.2% drop is evident in the current average compared to the previous average price target of $27.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1728680416_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Atlas Energy Solutions's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Chase Mulvehill</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Luke Lemoine</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Atlas Energy Solutions. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Atlas Energy Solutions compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Atlas Energy Solutions's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Atlas Energy Solutions's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AESI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Atlas Energy Solutions analyst ratings.</a>
<h2>About Atlas Energy Solutions</h2>
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the most active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
<h3>Atlas Energy Solutions: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Atlas Energy Solutions's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 77.71% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Atlas Energy Solutions's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Atlas Energy Solutions's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.39%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Atlas Energy Solutions's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.76%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.47, Atlas Energy Solutions adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AESI

Decoding 7 Analyst Evaluations For Atlas Energy Solutions

Cryptocurrency markets were trading higher before entering the weekend with altcoins also being pushed up.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$63,000.44</td>
<td>+5.8%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,459.54</td>
<td>+4.3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$145.88</td>
<td>+6.2%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.111</td>
<td>+6.2%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001775</td>
<td>+8.2%</td>
</tr>
</tbody>
</table>
</figure>
<h1 class="wp-block-heading">Notable Statistics:</h1>
<ul>
<li>IntoTheBlock data showed large transaction volume decreasing by 23.2% and daily active addresses up by 3.6%. Transactions greater than $100,000 were up from 7,555 to 8,264 in a single day. Exchanges netflows were down by 327.6%. Currently, 87% of Bitcoin holders made profits while 13% were at breakeven.</li>
<li>Coinglass data reported 38,216 traders were liquidated in the past 24 hours with the total liquidations at $115.88 million.</li>
</ul>
<h1 class="wp-block-heading">Notable Developments:</h1>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41297376/bitcoin-will-hit-250k-raoul-pal-says-why-the-gurus-top-5-crypto-predictions-matter-if-your">Bitcoin Will Hit $250K, Raoul Pal Says: Why The Guru&#8217;s Top 5 Crypto Predictions Matter If &#8216;You&#8217;re A Wage Slave&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41285570/tron-founder-justin-sun-appointed-prime-minister-of-a-crypto-focused-micronation-in-europe">Tron Founder Justin Sun Appointed &#8216;Prime Minister&#8217; Of A Crypto-Focused Micronation In Europe</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41297899/kamala-harris-receives-1-million-in-xrp-from-ripple-co-founder-chris-larsen">Kamala Harris Receives $1 Million In XRP From Ripple Co-Founder Chris Larsen</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41285163/tesla-themed-coins-spike-after-ev-giant-unveils-cybercab-robotaxi-why-you-should-be-carefu">Tesla-Themed Coins Spike After EV Giant Unveils &#8216;Cybercab&#8217; Robotaxi — Why You Should Be Careful</a></li>
</ul>
<h1 class="wp-block-heading">Top Gainers:</h1>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Ethena (CRYPTO: ENA)</td>
<td>&nbsp;$0.3366</td>
<td>+25.2%</td>
</tr>
<tr>
<td>Mog Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MOG</a>)</td>
<td>&nbsp;$0.051709&nbsp;</td>
<td>+24.2%</td>
</tr>
<tr>
<td>Worldcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WLD</a>)</td>
<td>&nbsp;$1.93</td>
<td>+14.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices trading higher beyond $62,000, crypto trader Javon Marks saw the crypto king still looking to reclaim its all-time highs of $73,700. Also, based on historical performance of a similar pattern, prices could also be set for a move much higher. He <a href="https://x.com/JavonTM1/status/1844741428028625321">predicted</a> the next target at $116,650.
Crypto analyst Miles Deutscher marked $59,000 as must hold level. He predicted not making any "major moves this weekend (apart from trading memes), as directionality is still a bit unclear."
He <a href="https://x.com/milesdeutscher/status/1844788856643592468">added</a> there needed to be a higher high to officially break downtrend structure.
Michael van de Poppe highlighted the trend switched and the next test is at $65,000.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The trend has switched! Despite the current sentiment, markets are already uptrending and I think that the acceleration is just around the corner for the whole market.<a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> made a higher, higher low, and found support at $60K. The next test at $65K, that&#39;s the one. <a href="https://t.co/CaU3jrFeSW">pic.twitter.com/CaU3jrFeSW</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1844800136855044167?ref_src=twsrc%5Etfw">October 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another crypto trader Seth <a href="https://x.com/seth_fin/status/1844813140866810204">advised</a> to not make any mistakes as the bull market is going on. He noted whales were accumulating and grabbing liquidity from the retail traders. He predicted the liquidity will help "ascend."
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41295451/bitcoin-rises-2-to-break-62k-trader-reports-90-to-100-bullish-signals">Bitcoin Rises 2% to Break $62K, Trader Reports &#8216;90% to 100% Bullish Signals&#8217;</a></li>
</ul>
Photo: Avi Rozen on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

$DOGE

$ETH

$MOG

$SHIB

$SOL

$WLD

Bitcoin, Ethereum, Dogecoin See Friday Gains, But Trader Warns '$59,000 Must Hold, No Major Moves Expected This Weekend'

As Florida's pivotal vote on recreational cannabis looms, investors are eyeing key opportunities in the market. The Viridian Credit Tracker ranks AYR Wellness (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>) as a strong buy, with a compelling 20% yield driven by its significant presence in Florida's cannabis market. With the potential for Florida voters to approve recreational use, AYR stands to gain considerably, making it a prime target for investors before the vote.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">AYR Wellness Offers 20% Yield: Capitalize on Florida's Potential Vote</h3>
According to the Viridian Credit Tracker from <a href="https://www.benzinga.com/topic/viridian-capital-advisors">Viridian Capital Advisors</a>, AYR's exposure to Florida's market gives it a unique advantage ahead of the state&#8217;s potential legalization of recreational cannabis. 
With a 20% trading yield, AYR outpaces many of its competitors. If <a href="https://www.benzinga.com/topic/florida-cannabis">Florida</a> approves recreational cannabis, AYR's valuation could see a substantial boost, making this stock a strategic buy for investors ahead of the vote.
<h3 class="wp-block-heading">Cresco Labs vs. Curaleaf: A 250 Basis Point Difference</h3>
Another <a href="https://dealtracker.viridianca.com/credit-tracker-by-industry-sector/">suggested pair trade</a> from the report is to buy Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) at a 12.6% yield and sell Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) at 10.1%. This trade offers investors a 250 basis point yield upgrade, backed by Cresco's solid financials and credit improvement. Investors looking for higher returns and credit strength should consider this opportunity.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/10/41277104/exclusive-80-growth-despite-the-chaos-how-dutchie-c3-defy-2024s-cannabis-slump"> EXCLUSIVE: 80% Growth Despite The Chaos: How Dutchie, C3 Defy 2024&#8217;s Cannabis Slump</a>
<h3 class="wp-block-heading">TerrAscend: Why 12% Yield Might Not Be Enough</h3>
In contrast, TerrAscend (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TRSSF#OTC">TRSSF</a>), which offers a 12% yield, is <a href="https://dealtracker.viridianca.com/credit-tracker-by-industry-sector/">recommended as a sell</a>. While TerrAscend remains a significant player in the cannabis industry, its lower yield and reduced exposure to Florida's growth potential make it less appealing compared to AYR.
<h3 class="wp-block-heading">Cannabist Faces Liquidity Challenges</h3>
Despite the attractive spreads among top stocks, Cannabist (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CCHWF#OTC">CCHWF</a>) ranks as the <a href="https://www.benzinga.com/markets/cannabis/24/10/41192369/lender-expresses-concern-over-cannabist-companys-pray-and-hope-approach">weakest credit in the group</a>, largely due to liquidity concerns following recent asset sales. Investors should note that Cannabist's lower credit rating may limit its near-term upside despite potential improvements in the future.
<h3 class="wp-block-heading">Take Action Now: Florida's Vote Could Change the Game</h3>
With Florida's cannabis market potentially expanding, investors looking to maximize gains should consider this pair trade: buy AYR at 20%, sell TerrAscend at 12%, and look into Cresco Labs at 12.6% versus Curaleaf at 10.1%. The <a href="https://www.benzinga.com/markets/cannabis/24/10/41240793/its-your-constitutional-right-how-you-can-break-the-senates-block-on-cannabis-legalization">vote could transform the landscape for cannabis stocks</a>, and taking action before this pivotal event could provide substantial returns.
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="583" height="546" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10141616/Viridian-Capital-Advisors-Viridian-Credit-Tracker-October-2024.jpg" alt="" class="wp-image-590060" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10141616/Viridian-Capital-Advisors-Viridian-Credit-Tracker-October-2024.jpg 583w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10141616/Viridian-Capital-Advisors-Viridian-Credit-Tracker-October-2024-300x281.jpg 300w" sizes="(max-width: 583px) 100vw, 583px" /><figcaption class="wp-element-caption">Courtesy of Viridian Capital Advisors </figcaption></figure>
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/10/41270886/sec-charges-magic-mushroom-co-minerco-in-8m-pump-and-dump-scheme"> SEC Charges &#8216;Magic Mushroom&#8217; Co. Minerco In $8M Pump-And-Dump Scheme</a>

Analyst Color

Cannabis

Small Cap Analysis

Technicals

Small Cap

AYRWF

CCHWF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

TRSSF

Why Cannabis Investors Should Make This Bold Move Before Florida's Vote: What To Buy And Sell Now

Trading Halt: Halted at 4:55:00 p.m. ET - Trading Halt: Halt News Pending

Bedrocan International, a producer of pharmaceutical-grade medicinal cannabis, is set to make a return to the Canadian market, reaffirming its long-held commitment to providing standardized medicinal cannabis for patients. The company recently acquired a facility in Scarborough, a strategic location that once served as its operational base in Canada, and has been granted a new cultivation license by Health Canada. Production is expected to begin in early 2025, marking Bedrocan's renewed presence in Canada after several years of absence.
"We have had a strictly pharmaceutical approach since our foundation in 2003. We use the knowledge we have acquired in more than twenty years of business to produce cannabis products that benefit patients exclusively," said Bedrocan's CEO Jaap Erkelens. Bedrocan's meticulous approach to production ensures consistent levels of THC and CBD in all of its products, offering patients a reliable, standardized therapeutic experience. This level of precision is critical for both patients and prescribing physicians who seek consistent outcomes from medical cannabis treatments.
In its return to the Canadian market, Bedrocan aims to introduce several of its standardized cannabis products, with the Bedrocan brand at the forefront. The company plans to distribute these products via a third party through the medical sales channel, providing registered patients with direct access to high-quality, medicinal cannabis.
The company's return follows a previous venture in Canada that ended with the termination of its partnership with Canopy Growth Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>). Despite this setback, Bedrocan remained steadfast in its desire to return to the Canadian market. "We are thrilled to be coming back to Canada," Erkelens said. "We look forward to serving patients in Canada and positively impacting the Canadian healthcare landscape."
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Cover image made with AI

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Omni Health

News

Latest news for Omni Health (OTC:OMHE) Stock

Tuesday, March 24, 2020